Novo Nordisk A/S Competitive Strategy & SWOT Analysis
Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
SWOT Analysis: Novo Nordisk A/S
Strengths
- Novo Nordisk has global scale, clinical depth, and manufacturing experience in diabetes and obesity GLP-1 medicines.
Weaknesses
- A large share of investor expectations depends on continued Ozempic and Wegovy growth.
Opportunities
- Obesity care, cardiovascular outcomes, oral formulations, and broader metabolic indications can expand the addressable market.
Threats
- Rival incretin drugs, compounding, payer restrictions, safety scrutiny, and supply constraints can pressure growth.
Market Position & Competitive Landscape
Novo Nordisk competes with Eli Lilly, Novartis, Pfizer, Johnson & Johnson, GSK, AstraZeneca, Roche, biosimilar manufacturers, and obesity-care entrants. Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.